Treating essential tremor is anything but simple.
Cala Trio makes it simple.
Learn more about this individualized wrist-worn neuromodulation therapy that effectively reduces hand tremors.
We can provide a comprehensive overview of Cala Trio therapy and answer your questions through a virtual inservice. Request a virtual inservice today.
The largest therapeutic clinical trial in ET, PROSPECT, was conducted using the Cala Trio device. The data demonstrated that the therapy is equivalent in effectiveness to medication by utilizing the electrical stimulation—the mechanism of surgical interventions.
Watch this video for an overview of PROSPECT Data.
Prescribing Cala Trio for your patients is easy
Now you can prescribe a treatment personalized to your patients’ unique tremor patterns using advanced targeted therapy. With Cala Trio, you can finally breakthrough the barrier of inadequate options to deliver care. The FDA-cleared, Cala Trio therapy avoids common side-effects and risks associated with traditional ET treatment options.
Learn More About Cala Trio Therapy from Movement Disorder Specialists
In the PROSPECT study, a wrist-worn neuromodulation device Cala Trio by CalaHealth, Inc. provided symptomatic relief for essential tremor (ET).
Dr. Dhall is an Associate Professor of Neurology and the Director of Neurodegenerative Disorders at University of Arkansas for Medical Sciences. He previously directed the National Parkinson Foundation (NPF) Center of Excellence at the Parkinsons Institute in Sunnyvale, CA and Barrow Neurological Institute in Phoenix, AZ. We sat down with Dr. Dhall to discuss the latest in non-invasive treatment for essential tremor.